Senti Biosciences Holdings, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Senti Biosciences Holdings, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Cash Cushion Ratio: Debt, after subtracting cash, is 2.1 times its market value (net debt). Lower than 97% of Healthcare companies in United States.
- Shareholder Slice Ratio: Share count rose 601% in 3 years, so each share's slice of the company became smaller. Bigger rise in share count than 87% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-11.2×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 52% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
1/3 · 1/3Sales grew in 1 of the last 3 years; profit grew in 1 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales fell 99%
Sales fell 99% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-99% / -72%In 3 years sales changed by -99% while total assets changed by -72%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
-8.2×Operating cash was negative last year, while some debt falls due within a year.
Higher than 56% of Healthcare companies in United States.
Cash Cushion Ratio
2.1× debtDebt, after subtracting cash, is 2.1 times its market value (net debt).
Lower than 97% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
Senti Biosciences Holdings, Inc. made a loss over the last year. Senti Biosciences Holdings, Inc. owes $1.10 for every $1 it owns. Senti Biosciences Holdings, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossSenti Biosciences Holdings, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
-1.74Senti Biosciences Holdings, Inc.'s book value is negative (it owes more than it owns), so P/B is not meaningful.
Market cap
$6 MThe total market value of all of Senti Biosciences Holdings, Inc.'s shares at today's price (share price × number of shares), smaller than 91% of Healthcare companies in United States. PosiCap size class: Nano Cap.
Net worth (book value)
NegativeSenti Biosciences Holdings, Inc.'s net worth is negative ($3 M below zero, balance sheet 30 Jun 2026): it owes more than it owns, so book value per share and P/B are not meaningful.
Return on equity (ROE)
-466.5%Senti Biosciences Holdings, Inc. lost 466.5% of its shareholders' money over the last year, lower than 93% of Healthcare companies in United States.
Owes vs Owns
1.10×Senti Biosciences Holdings, Inc. owes $1.10 for every $1 it owns, so it owes more than it owns, higher than 89% of Healthcare companies in United States.
Dividend yield
NoneSenti Biosciences Holdings, Inc. does not currently pay a dividend.
Profit growth
LossSenti Biosciences Holdings, Inc. made a loss in each of the last two years.
Profit margin
-279263.6%Senti Biosciences Holdings, Inc. lost $279264 for every $100 of revenue.
Cash vs debt
Net debtSenti Biosciences Holdings, Inc. had $12 M more debt than cash (net debt) at Dec 2025.
Questions
What is Senti Biosciences Holdings, Inc.'s return on equity?
Senti Biosciences Holdings, Inc. lost 466.5% of its shareholders' money over the last year, lower than 93% of Healthcare companies in United States.
How much does Senti Biosciences Holdings, Inc. owe compared with what it owns?
Senti Biosciences Holdings, Inc. owes $1.10 for every $1 it owns, so it owes more than it owns, higher than 89% of Healthcare companies in United States.
Does Senti Biosciences Holdings, Inc. pay a dividend?
No. Senti Biosciences Holdings, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.